{
    "clinical_study": {
        "@rank": "139434", 
        "acronym": "LOTUS", 
        "arm_group": [
            {
                "arm_group_label": "Pharmacologic therapy", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "TAE and pharmacologic therapy", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to verify if adding a locoregional treatment of liver\n      metastasis (with trans-arterial embolization-TAE) to a medical treatment (with Octreotide\n      LAR and eventually in combination with other medical treatments of proven efficacy), can\n      prolong the progression free survival of patients affected by neuroendocrine tumors (NET)\n      with inoperable liver metastases"
        }, 
        "brief_title": "Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Neuroendocrine Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neuroendocrine Tumors", 
                "Liver Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "NET patients with unresectable hepatic metastases at diagnosis or who have not received any\n      antineoplastic therapy for metastatic disease will be registered in the study and sent to a\n      screening phase. Randomization will be proposed to patients with progressive  hepatic or\n      symptomatic disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        At registration\n\n          -  Diagnosis of  NET of gastroenteropancreatic (GEP), pulmonary or unknown primary site\n             origin\n\n          -  Unresectable liver metastases, according  the judgment of surgeon, (the reasons for\n             the opinion of surgeon should be made explicit)\n\n          -  Hepatic involvement  \u226450% volume of the organ\n\n          -  Well (G1) or medium (G2) differentiated histology (according to WHO 2010\n             classification)\n\n          -  Ki67 \u2264 20% (G1-G2)\n\n          -  Life expectancy > 6 months\n\n          -  Age \u2265 18 and < 80 years\n\n        At  randomization\n\n          -  Confirmed criteria as per registration\n\n          -  Radiological progression of hepatic localizations, verified during screening phase,\n             or presence of symptoms requiring an immediate treatment with somatostatin analogues\n             (I.E. in case of a functioning tumour, that doesn't need of a symptomatic therapy\n             with analogues of somatostatin [insulinoma, gastrinoma, ACTHoma], it is necessary to\n             wait for radiological progression)\n\n        Exclusion Criteria:\n\n        At registration\n\n          -  Previous loco-regional postsurgical treatment\n\n          -  Low differentiated histology\n\n          -  Severe concomitant morbidities such as: severe coagulopathy, severe liver failure (to\n             be detailed), renal failure (creatinine > 2.0 mg/dl) and heart failure (NYHA 3-4 or\n             instable ischemic heart disease),  contraindicating the interventional procedure or\n             influencing the general prognosis (Investigator to provide details of exclusion)\n\n          -  Extrahepatic metastasis in critical locations as: brain, spinal cord, lung with\n             respiratory impairment, symptomatic vertebral lesions\n\n        At randomization\n\n          -  Patients with progression of disease only on the extra-hepatic localizations during\n             screening phase\n\n          -  Patients with progression disease  on critical location such as: brain, spinal cord,\n             lung with respiratory impairment, symptomatic vertebral lesions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755182", 
            "org_study_id": "LOTUS", 
            "secondary_id": "2011-006097-76"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Pharmacologic therapy", 
                    "TAE and pharmacologic therapy"
                ], 
                "description": "30 mg IM every 28 days (the addition of other pharmacologic therapies of proven efficacy in NET is permitted)", 
                "intervention_name": "Octreotide LAR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TAE and pharmacologic therapy", 
                "description": "after randomization, and after 3 months", 
                "intervention_name": "TAE", 
                "intervention_type": "Procedure", 
                "other_name": "transarterial embolization"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Octreotide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "locoregional treatment", 
            "liver metastases", 
            "transarterial embolization", 
            "upfront treatment", 
            "inoperable", 
            "octreotide", 
            "gastroenteropancreatic (GEP)primary", 
            "pulmonary primary", 
            "primary unknown origin", 
            "systemic therapy"
        ], 
        "lastchanged_date": "February 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Albano Laziale", 
                        "country": "Italy"
                    }, 
                    "name": "Albano Laziale Ospedale \"Regina Apoltolorum\""
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ferrara", 
                        "country": "Italy"
                    }, 
                    "name": "Universit\u00e0 di Ferrara"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy"
                    }, 
                    "name": "Universit\u00e0 di Genova"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Nazionale Tumori"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Europeo di Oncologia"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "MIlano", 
                        "country": "Italy"
                    }, 
                    "name": "Ospedale San Raffaele"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Nazionale dei Tumori"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Istituto Regina Elena"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Udine", 
                        "country": "Italy"
                    }, 
                    "name": "Azienda Ospedaliero-Universitaria S.M. della Misericordia di Udine"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Verona", 
                        "country": "Italy"
                    }, 
                    "name": "Universit\u00e0 di Verona Policlinico GB Rossi"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase 3 Trial Evaluating the Efficacy of Locoregional Treatment With Transarterial Embolization (TAE) for Liver Metastases, in Combination With Octreotide LAR, in Patients With Neuroendocrine Tumor and Inoperable Liver Metastasis.", 
        "other_outcome": {
            "description": "clinical factors will be explored in relation to patient outcomes", 
            "measure": "exploratory analysis of prognostic factors", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "overall_contact": {
            "email": "francesco.perrone@usc-intnapoli.net", 
            "last_name": "Francesco Perrone, M.D., Ph.D.", 
            "phone": "+39 081 5903571"
        }, 
        "overall_contact_backup": {
            "email": "marilina.piccirillo@usc-intnapoli.net", 
            "last_name": "Marilina Piccirillo, M.D.", 
            "phone": "+39 081 5903383"
        }, 
        "overall_official": [
            {
                "affiliation": "Federico II University", 
                "last_name": "A Colao, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Federico II University", 
                "last_name": "A Faggiano, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "NCI Naples", 
                "last_name": "R D'Angelo, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "NCI Naples", 
                "last_name": "F Fiore, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "NCI Naples", 
                "last_name": "F Perrone, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Second University of Naples", 
                "last_name": "C Gallo, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "NCI Naples", 
                "last_name": "MC Piccirillo, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "progression free survival", 
            "safety_issue": "No", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755182"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "number of objective responses", 
                "safety_issue": "No", 
                "time_frame": "measured at 3 months and 6 months"
            }, 
            {
                "measure": "changes in quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 6 months"
            }, 
            {
                "measure": "worst grade adverse event per patient", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }
        ], 
        "source": "National Cancer Institute, Naples", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Federico II University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Second University of Naples", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Cancer Institute, Naples", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}